Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
In the latest session, Sana Biotechnology Inc (NASDAQ: SANA) closed at $2.43 down -6.90% from its previous closing price of $2.61. In other words, the price has decreased by -$6.90 from its previous closing price. On the day, 3.04 million shares were traded.
Ratios:
For a deeper understanding of Sana Biotechnology Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.47 and its Current Ratio is at 4.47. In the meantime, Its Debt-to-Equity ratio is 0.33 whereas as Long-Term Debt/Eq ratio is at 0.29.
On June 26, 2024, Rodman & Renshaw started tracking the stock assigning a Buy rating and target price of $16.Rodman & Renshaw initiated its Buy rating on June 26, 2024, with a $16 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Feb 18 ’25 when CHRISTIAN HORDO & KATHARINE HO bought 75,000 shares for $3.16 per share.
CHRISTIAN HORDO & KATHARINE HO bought 75,000 shares of SANA for $289,500 on Jan 16 ’25. On Jan 08 ’25, another insider, FMR LLC, who serves as The insider 1 of the company, sold 290,912 shares for $6.49 each. As a result, the insider received 1,887,320 and left with 4,541,511 shares of the company.
Stock Price History:
Over the past 52 weeks, SANA has reached a high of $12.00, while it has fallen to a 52-week low of $1.52. The 50-Day Moving Average of the stock is -11.23%, while the 200-Day Moving Average is calculated to be -44.46%.
Shares Statistics:
A total of 223.11M shares are outstanding, with a floating share count of 124.25M. Insiders hold about 44.35% of the company’s shares, while institutions hold 55.97% stake in the company.
Earnings Estimates
Its stock is currently analyzed by 2.0 different market analysts. The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between -$1.08 and -$1.2 for the fiscal current year, implying an average EPS of -$1.14. EPS for the following year is -$0.97, with 2.0 analysts recommending between -$0.8 and -$1.15.
